ArticleTranslational vision science & technology2016
Efficacy and Safety of Human Retinal Progenitor Cells.
Article in Translational vision science & technology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Direct Chemical Reprogramming of Human Fibroblasts into Retinal Progenitor-like Cells for Ocular Delivery.Journal of functional biomaterials · 2026Article
- Review
- Animal models for the evaluation of retinal stem cell therapies.Progress in retinal and eye research · 2025Review
- Techniques for subretinal injections in animals.Veterinary ophthalmology · 2025Review
- Hyaluronan-CD44 Interaction Regulates Mouse Retinal Progenitor Cells Migration, Proliferation and Neuronal Differentiation.Stem cell reviews and reports · 2023Article
- GMP-grade human neural progenitors delivered subretinally protect vision in rat model of retinal degeneration and survive in minipigs.Journal of translational medicine · 2023Article
- Immune Responses to Sequential Binocular Transplantation of Allogeneic Retinal Progenitor Cells to the Vitreous Cavity in Mice.International journal of molecular sciences · 2023Article
- Automating iPSC generation to enable autologous photoreceptor cell replacement therapy.Journal of translational medicine · 2023Article
- Advances in cell therapies using stem cells/progenitors as a novel approach for neurovascular repair of the diabetic retina.Stem cell research & therapy · 2022Review
- Outer Retinal Cell Replacement: Putting the Pieces Together.Translational vision science & technology · 2021Review
- Human Retinal Progenitor Cells Derived Small Extracellular Vesicles Delay Retinal Degeneration: A Paradigm for Cell-free Therapy.Frontiers in pharmacology · 2021Article
- Stem/progenitor cell-based transplantation for retinal degeneration: a review of clinical trials.Cell death & disease · 2020Review
- Neuronal Reprogramming for Tissue Repair and Neuroregeneration.International journal of molecular sciences · 2020Review
- Intravitreal Injection of Human Retinal Progenitor Cells for Treatment of Retinal Degeneration.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Organoid-derived C-KitNature communications · 2019Article
- Pluripotent Stem Cells for Retinal Tissue Engineering: Current Status and Future Prospects.Stem cell reviews and reports · 2018Review
- Cellular regeneration strategies for macular degeneration: past, present and future.Eye (London, England) · 2018Review
- Transplanted hESC-Derived Retina Organoid Sheets Differentiate, Integrate, and Improve Visual Function in Retinal Degenerate Rats.Investigative ophthalmology & visual science · 2018Article
- Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients.Stem cell research & therapy · 2017Article
- Clinical studies using stem cells for treatment of retinal diseases: state of the art.Arquivos brasileiros de oftalmologiaReview
Corrections and comments
- Erratum issuedErratum.2016
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeWe assessed the long-term efficacy and safety of human retinal progenitor cells (hRPC) using established rodent models.
methodsEfficacy of hRPC was tested initially in Royal College of Surgeons (RCS) dystrophic rats immunosuppressed with cyclosporine/dexamethasone. Due to adverse effects of dexamethasone, this drug was omitted from a subsequent dose-ranging study, where different hRPC doses were tested for their ability to preserve visual function (measured by optokinetic head tracking) and retinal structure in RCS rats at 3 to 6 months after grafting. Safety of hRPC was assessed by subretinal transplantation into wild type (WT) rats and NIH-III nude mice, with analysis at 3 to 6 and 9 months after grafting, respectively.
resultsThe optimal dose of hRPC for preserving visual function/retinal structure in dystrophic rats was 50,000 to 100,000 cells. Human retinal progenitor cells integrated/survived in dystrophic and WT rat retina up to 6 months after grafting and expressed nestin, vimentin, GFAP, and
conclusionsHuman retinal progenitor cells appear safe and efficacious in the preclinical models used here. TRANSLATIONAL RELEVANCE: Human retinal progenitor cells could be deployed during early stages of retinal degeneration or in regions of intact retina, without adverse effects on visual function. The ability of dexamethasone to reduce baseline visual acuity in RCS dystrophic rats has important implications for the interpretation of preclinical and clinical cell transplant studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.